Fas/Fas配体系统在乳腺癌中的预后价值。
Prognostic value of the Fas/Fas ligand system in breast cancer.
作者信息
Bębenek Marek, Duś Danuta, Koźlak Joanna
机构信息
1 Department of Surgical Oncology, Regional Comprehensive Cancer Center, Wroclaw, Poland.
出版信息
Contemp Oncol (Pozn). 2013;17(2):120-2. doi: 10.5114/wo.2013.34612. Epub 2013 Apr 29.
Abstract
Fas and its ligand (FasL) are known to play a crucial role in the genetically controlled mechanism of cell death, and their deregulation in cancer cells is involved in the immune escape of the tumor. The aim of this review is to analyze the current knowledge on the prognostic value of Fas/FasL in breast cancer patients. Both the results of other authors and our own experiences indicate that the lack of Fas ligand, and particularly Fas, is related to a significantly worse prognosis. It probably results from the resistance of Fas-deficient breast tumors to the mechanisms of apoptosis. On the other hand, some results suggest that the Fas/FasL-dependent mechanisms of tumor spread may be different for various target tissues. The expression of the Fas/Fas-ligand system has potential prognostic application in view of current knowledge, and consequently should be considered as an additional prognostic factor in breast cancer patients.
摘要
已知Fas及其配体（FasL）在细胞死亡的基因控制机制中发挥关键作用，它们在癌细胞中的失调与肿瘤的免疫逃逸有关。本综述的目的是分析目前关于Fas/FasL在乳腺癌患者中的预后价值的知识。其他作者的结果以及我们自己的经验均表明，Fas配体的缺失，尤其是Fas的缺失，与显著更差的预后相关。这可能是由于缺乏Fas的乳腺肿瘤对凋亡机制具有抗性。另一方面，一些结果表明，Fas/FasL依赖性的肿瘤扩散机制可能因不同的靶组织而有所不同。鉴于目前的知识，Fas/Fas配体系统的表达具有潜在的预后应用价值，因此应被视为乳腺癌患者的一个额外预后因素。
相似文献
1
Prognostic value of the Fas/Fas ligand system in breast cancer.Fas/Fas配体系统在乳腺癌中的预后价值。
Contemp Oncol (Pozn). 2013;17(2):120-2. doi: 10.5114/wo.2013.34612. Epub 2013 Apr 29.
2
Fas (APO-1/CD95) ligand and Fas expression in renal cell carcinomas: correlation with the prognostic factors.肾细胞癌中Fas（APO-1/CD95）配体与Fas的表达：与预后因素的相关性
Arch Pathol Lab Med. 2000 May;124(5):687-93. doi: 10.5858/2000-124-0687-FACLAF.
3
Tumour Fas ligand:Fas ratio greater than 1 is an independent marker of relative resistance to tamoxifen therapy in hormone receptor positive breast cancer.肿瘤Fas配体与Fas的比值大于1是激素受体阳性乳腺癌中对他莫昔芬治疗相对耐药的独立标志物。
Breast Cancer Res. 2002;4(5):R9. doi: 10.1186/bcr456. Epub 2002 Jun 21.
4
Prognostic relevance of altered Fas (CD95)-system in human breast cancer.人类乳腺癌中Fas（CD95）系统改变的预后相关性
Int J Cancer. 2000 Mar 20;89(2):127-32. doi: 10.1002/(sici)1097-0215(20000320)89:2<127::aid-ijc5>3.0.co;2-4.
5
[The significance of Fas/FasL molecular system in breast cancer].[Fas/FasL分子系统在乳腺癌中的意义]
Rev Med Chir Soc Med Nat Iasi. 2004 Apr-Jun;108(2):440-4.
6
On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.以多发性骨髓瘤为模型探讨Fas（Apo-1/CD95）配体（FasL）在免疫赦免组织和癌细胞中表达的作用及意义
Leuk Lymphoma. 1998 Nov;31(5-6):477-90. doi: 10.3109/10428199809057607.
7
Fas and Fas ligand as prognostic factors in human breast carcinoma.Fas和Fas配体作为人类乳腺癌的预后因素。
Med Sci Monit. 2006 Nov;12(11):CR457-61.
8
FasL:Fas ratio--a prognostic factor in breast carcinomas.Fas配体与Fas的比值——乳腺癌的一个预后因素。
Cancer Res. 2000 Feb 15;60(4):822-8.
9
Altered expression of FAS system is related to adverse clinical outcome in stage I-II breast cancer patients treated with adjuvant anthracycline-based chemotherapy.FAS系统表达改变与接受基于蒽环类药物辅助化疗的I-II期乳腺癌患者的不良临床结局相关。
Clin Cancer Res. 2004 Feb 15;10(4):1360-5. doi: 10.1158/1078-0432.ccr-1092-03.
10
A Fas Ligand (FasL)-Fused Humanized Antibody Against Tumor-Associated Glycoprotein 72 Selectively Exhibits the Cytotoxic Effect Against Oral Cancer Cells with a Low FasL/Fas Ratio.一种针对肿瘤相关糖蛋白72的Fas配体（FasL）融合人源化抗体，在FasL/Fas比例较低的情况下，对口腔癌细胞选择性地表现出细胞毒性作用。
Mol Cancer Ther. 2017 Jun;16(6):1102-1113. doi: 10.1158/1535-7163.MCT-16-0314. Epub 2017 Mar 14.
引用本文的文献
1
Comparison of Niosomal formulation of citrus limon peel extracts and doxorubicin effects on MCF-7 and MDA-MB-231 human breast cancer cells.柠檬皮提取物的纳米脂质体制剂与阿霉素对MCF-7和MDA-MB-231人乳腺癌细胞作用的比较。
Sci Rep. 2025 Aug 4;15(1):28359. doi: 10.1038/s41598-025-10498-w.
2
Reconstituting Immune Surveillance in Breast Cancer: Molecular Pathophysiology and Current Immunotherapy Strategies.重建乳腺癌免疫监测：分子病理生理学和当前免疫治疗策略。
Int J Mol Sci. 2021 Nov 6;22(21):12015. doi: 10.3390/ijms222112015.
3
Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression.腔面型乳腺癌：复发风险和肿瘤相关免疫抑制。
Mol Diagn Ther. 2021 Jul;25(4):409-424. doi: 10.1007/s40291-021-00525-7. Epub 2021 May 11.
4
NUP210 and MicroRNA-22 Modulate Fas to Elicit HeLa Cell Cycle Arrest.NUP210 和 MicroRNA-22 调节 Fas 诱导 HeLa 细胞周期停滞。
Yonsei Med J. 2020 May;61(5):371-381. doi: 10.3349/ymj.2020.61.5.371.
5
The prognostic role of NK cells and their ligands in squamous cell carcinoma of the head and neck: a systematic review and meta-analysis.自然杀伤细胞及其配体在头颈部鳞状细胞癌中的预后作用：一项系统评价和荟萃分析。
Oncoimmunology. 2020 Apr 23;9(1):1747345. doi: 10.1080/2162402X.2020.1747345. eCollection 2020.
6
A Computational Statistics Approach to Evaluate Blood Biomarkers for Breast Cancer Risk Stratification.计算统计学方法评估乳腺癌风险分层的血液生物标志物。
Horm Cancer. 2020 Feb;11(1):17-33. doi: 10.1007/s12672-019-00372-3. Epub 2019 Dec 19.
7
Weighted Fused Pathway Graphical Lasso for Joint Estimation of Multiple Gene Networks.用于多基因网络联合估计的加权融合路径图模型选择法
Front Genet. 2019 Jul 22;10:623. doi: 10.3389/fgene.2019.00623. eCollection 2019.
8
Synergistic effect of granzyme B-azurin fusion protein on breast cancer cells.粒细胞酶 B-天青蛋白融合蛋白对乳腺癌细胞的协同作用。
Mol Biol Rep. 2019 Jun;46(3):3129-3140. doi: 10.1007/s11033-019-04767-x. Epub 2019 Apr 1.
9
HET0016 decreases lung metastasis from breast cancer in immune-competent mouse model.HET0016可减少免疫健全小鼠模型中乳腺癌的肺转移。
PLoS One. 2017 Jun 13;12(6):e0178830. doi: 10.1371/journal.pone.0178830. eCollection 2017.
10
Mechanism of immune evasion in breast cancer.乳腺癌的免疫逃逸机制。
Onco Targets Ther. 2017 Mar 14;10:1561-1573. doi: 10.2147/OTT.S126424. eCollection 2017.
本文引用的文献
1
Fas/Fas-ligand expressions in primary breast cancer are significant predictors of its skeletal spread.原发性乳腺癌中Fas/Fas配体的表达是其骨骼转移的重要预测指标。
Anticancer Res. 2007 Jan-Feb;27(1A):215-8.
2
Fas and Fas ligand as prognostic factors in human breast carcinoma.Fas和Fas配体作为人类乳腺癌的预后因素。
Med Sci Monit. 2006 Nov;12(11):CR457-61.
3
Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression.FAS/CD95/APO-1在尿路上皮癌中的预后影响：Fas表达降低与疾病进展相关。
Br J Cancer. 2005 Sep 5;93(5):544-51. doi: 10.1038/sj.bjc.6602732.
4
Fas/CD95 signaling rather than angiogenesis or proliferative activity is a useful prognostic factor in patients with resected liver metastases from colorectal cancer.对于接受了结直肠癌肝转移灶切除的患者，Fas/CD95信号通路而非血管生成或增殖活性是一个有用的预后因素。
Int J Colorectal Dis. 2005 Nov;20(6):477-84. doi: 10.1007/s00384-004-0708-z. Epub 2005 Apr 22.
5
6
Prognostic impact of Fas ligand on hepatocellular carcinoma after hepatectomy.Fas配体对肝切除术后肝细胞癌的预后影响
World J Surg. 2004 Aug;28(8):792-6. doi: 10.1007/s00268-004-7254-2. Epub 2004 Aug 3.
7
Fas and Fas ligand: Expression and soluble circulating levels in bile duct carcinoma.Fas与Fas配体：胆管癌中的表达及可溶性循环水平
Oncol Rep. 2004 Jun;11(6):1183-6.
8
Altered expression of FAS system is related to adverse clinical outcome in stage I-II breast cancer patients treated with adjuvant anthracycline-based chemotherapy.FAS系统表达改变与接受基于蒽环类药物辅助化疗的I-II期乳腺癌患者的不良临床结局相关。
Clin Cancer Res. 2004 Feb 15;10(4):1360-5. doi: 10.1158/1078-0432.ccr-1092-03.
9
Death receptor-induced cell killing.死亡受体诱导的细胞杀伤。
Cell Signal. 2004 Feb;16(2):139-44. doi: 10.1016/j.cellsig.2003.08.007.
10
Diagnostic and prognostic value of fas and telomeric-repeat binding factor-1 genes in adrenal tumors.fas和端粒重复结合因子-1基因在肾上腺肿瘤中的诊断和预后价值
J Clin Endocrinol Metab. 2003 Aug;88(8):3690-3. doi: 10.1210/jc.2002-020965.
Zotero 插件